tella Inc. | Income Statement

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
Sales/Revenue
1,540
1,866
1,909
1,802
958
Cost of Goods Sold (COGS) incl. D&A
595
890
1,031
962
392
Gross Income
945
976
878
840
566
SG&A Expense
943
1,288
1,487
1,462
811
EBIT
1,540
312
609
623
245
Unusual Expense
19
-
387
427
404
Non Operating Income/Expense
-
7
1
237
24
Interest Expense
7
8
8
8
6
Pretax Income
23
330
1,013
853
634
Income Tax
12
65
3
25
5
Consolidated Net Income
35
395
1,016
878
639
Net Income
58
403
991
919
644
Net Income After Extraordinaries
58
403
991
919
644
Net Income Available to Common
58
403
991
919
644
EPS (Basic)
4.44
29.27
71.07
65.66
40.81
Basic Shares Outstanding
13
14
14
14
16
EPS (Diluted)
4.44
29.27
71.07
65.66
40.81
Diluted Shares Outstanding
13
14
14
14
16
EBITDA
1,706
126
397
484
239
Other Operating Expense
1,538
-
-
-
-
Non-Operating Interest Income
-
-
-
2
1
Minority Interest Expense
24
8
25
41
5
Equity in Affiliates (Pretax)
-
6
9
32
2

About tella

View Profile
Address
Mitsuihanagiri Building, 1/F
Tokyo Tokyo 160
Japan
Employees -
Website http://www.tella.jp
Updated 09/14/2018
tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It also offers technology and know-how to medical institutions such as university hospitals and national hospitals. It operates through the following business segments: Cell Medicine, Medical Support, and Pharmaceuticals.